Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07167758 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating TRIV-509 in Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Triveni Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT07167758: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Triveni Bio.
NCT07167758 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Triveni Bio. The registered enrollment target is 90 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07167758, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Triveni Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 will cross over and receive 4 doses of the other study intervention. The study duration for individual participants is up to 57 weeks, including a Screening period of up to 30 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TRIV-509
Study Locations (20)
Florida
- Triveni Bio Site #3 - Miami
- Triveni Bio Site #7 - Tampa
- Triveni Bio Site #9 - Tampa
Texas
- Triveni Bio Site #16 - Bellaire
- Triveni Bio Site #5 - Dallas
- Triveni Bio Site #2 - Dallas
Other
- Triveni Bio Site #32 - Lovech
- Triveni Bio Site #38 - Pleven
- Triveni Bio Site #39 - Sofia
California
- Triveni Bio Site #11 - Fountain Valley
- Triveni Bio Site #4 - San Diego
Indiana
- Triveni Bio Site #6 - Indianapolis
- Triveni Bio Site #10 - South Bend
Pennsylvania
- Triveni Bio Site #1 - Camp Hill
- Triveni Bio Site #20 - Pittsburgh
Sofia-Grad
- Triveni Bio Site #35 - Sofia
- Triveni Bio Site #36 - Sofia
Utah
- Triveni Bio Site #14 - Springville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT07167758 shows while recruiting
NCT07167758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07167758 names 20 study sites across 10 states, led by Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07167758 about?
NCT07167758 is a clinical study titled "A Study Evaluating TRIV-509 in Atopic Dermatitis". The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 doses of the study intervention that they are randomized to (TRIV-509 or placebo), and at Week 16 wi...
What is the current status of trial NCT07167758?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-08-26. Estimated completion is 2027-06.
What conditions does trial NCT07167758 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07167758?
The interventions under investigation include: Placebo (DRUG), TRIV-509 (DRUG).
Who is sponsoring clinical trial NCT07167758?
This trial is sponsored by Triveni Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07167758 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07167758's enrollment target sits among peer trials
90 90th of 150 higher than 58 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI